For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

The NHS has announced that the drug, abiraterone, will be offered to men with high-risk prostate cancer that has not yet ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data. Among patients with metastatic hormone-sensitive prostate cancer, the ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Prostate cancer is the second leading cause of cancer-related deaths among American men, claiming almost 35,000 lives annually. Androgens, male sex hormones, fuel the growth of most prostate tumors by ...

Thousands of men with prostate cancer will be given a life-extending drug on the NHS, following a three-year battle to expand ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...